Komori
Kohjin Bio (177A) · RiskRestated

Soaring Raw Material and Energy Prices and Supply Difficulties

First written in FY2024. 1 of 4 entries say "Materialised", first in FY2025-H1. Latest entry: FY2026.

4entries
3years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2024MaterialisedFY2025-H1MitigatedFY20252024: 220242025: 120252026: 12026
Same theme, other companies
Addressing Supply Constraints Through Material Substitution and Supplier DiversificationA theme 45 companies write about · 6 as a headwind · 39 as a tailwind

17 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 45 companies compared. The sentences above are computed from all 45.
Full recordFilings, disclosures and news, newest first
  1. FY2026RestatedAnnual report

    「The Group procures raw materials in Japan and overseas and is progressively selecting alternative suppliers in the supply chain for raw materials used in key products, with the aim of ensuring stable supplies. However, if soaring raw-material prices affect product costs, or if fluctuations in the supply-demand balance for raw materials, domestic or overseas regulations, quality problems at raw-material manufacturers or other factors make raw materials difficult to obtain over an extended period, the Group may be unable to manufacture or sell its products.」

    The risk of soaring raw-material and energy prices and supply difficulties, as well as measures involving the selection of alternative supply chains, remains ongoing.
  2. FY2025MitigatedAnnual report

    「Although sales of cell-processing products were temporarily suspended during the period while the raw materials were being reviewed, sales of those products resumed in February 2025.」

    It states that the review of raw materials resulted in suspended sales and lower revenue, but sales resumed in February 2025.
  3. FY2025-H1MaterialisedAnnual report

    「In addition, sales of cell-processing-related products have been temporarily suspended due to the impact of reviewing the raw materials used in those products, and sales of the product group have declined from the initial plan.」

    The suspension of sales and decline in revenue of cell-processing-related products have actually occurred as a result of reviewing the raw materials used.
  4. FY2024First statedAnnual report

    「If soaring raw-material prices affect product costs, or if fluctuations in the supply-demand balance for raw materials, domestic or overseas regulations, quality problems at raw-material manufacturers or other factors make raw materials difficult to obtain over an extended period, the Group may be unable to manufacture or sell its products.」

    It is proceeding with the selection of alternative supply chains and aiming to ensure stable supplies.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Kohjin Bio yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Soaring Raw Material and Energy Prices and Supply Difficulties | Kohjin Bio Co.,Ltd. (177A) | Komori